©The Author(s) 2022.
World J Clin Cases. Dec 26, 2022; 10(36): 13304-13312
Published online Dec 26, 2022. doi: 10.12998/wjcc.v10.i36.13304
Published online Dec 26, 2022. doi: 10.12998/wjcc.v10.i36.13304
Table 2 Serum Spondin-2 expression in patients with different clinicopathological features of cervical cancer
| Clinical pathology | High Spondin-2 group (n = 101) | Low Spondin-2 group (n = 46) | χ2 value | P value |
| Pathological type | ||||
| Squamous cell carcinoma | 70 | 31 | 0.595 | 0.743 |
| Adenocarcinoma | 18 | 7 | ||
| Adenosquamous carcinoma | 13 | 8 | ||
| FIGO stage | ||||
| Stage I–II | 50 | 41 | 10.501 | 0.001 |
| Stage III | 51 | 5 | ||
| Nerve invasion | ||||
| Yes | 72 | 20 | 10.438 | 0.001 |
| No | 29 | 26 | ||
| Vascular invasion | ||||
| Yes | 57 | 12 | 11.688 | 0.001 |
| No | 44 | 34 | ||
| Lymph node metastasis | ||||
| Yes | 66 | 21 | 5.075 | 0.024 |
| No | 35 | 25 |
- Citation: Zhang LL, Lin S, Zhang Y, Yao DM, Du X. Serum Spondin-2 expression, tumor invasion, and antitumor immune response in patients with cervical cancer. World J Clin Cases 2022; 10(36): 13304-13312
- URL: https://www.wjgnet.com/2307-8960/full/v10/i36/13304.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i36.13304